OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology Communications is 37. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population	148
Issue Information	134
Targeting hepatocyte-specific SLC2A8 blocks hepatic steatosis and dissociates TCA cycle flux inhibition from glutamine anaplerosis	132
HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells	96
CD8 TRM-like T cells expressing perforin and IFN-γ define a pediatric activated T-cell acute liver failure endotype	77
Quality improvement in hepatology requires a chronic care framework	69
Reduced short-term survival following liver transplant in patients with acute-on-chronic liver failure: Reevaluating OPTN data	69
Erratum: Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study	66
Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease	65
Association between widespread pain and associated symptoms in patients with cirrhosis	65
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia	64
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants	62
A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer	53
Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	52
Effect of glucagon-like peptide-1 receptor agonists on histologic MASH: A meta-analysis of randomized controlled trials	52
Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas	51
Medical malpractice claims in Hepatology: Rates, Reasons, and Results	50
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda	49
Visualizing in situ viral replication across the natural history of chronic HBV infection	48
Pain in chronic liver disease compared to other chronic conditions: Results from a contemporary nationally representative cohort study	46
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?	45
Aramchol attenuates fibrosis in mouse models of biliary fibrosis and blocks the TGFβ-induced fibroinflammatory mediators in cholangiocytes	44
Increasing nonalcoholic fatty liver disease–related mortality rates in the United States from 1999 to 2022	43
Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages	43
Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH	43

Co‐regulation of hepatic steatosis by ferritinophagy and unsaturated fatty acid supply	42
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno‐oncology: A network meta‐analysis of randomized sorafenib‐controlled trials	42
Granulomatous liver diseases	41
Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency	40
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database	38
Development and evaluation of a virtual reality driving test for patients with cirrhosis	38
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease	38
Complementary and alternative medicines and liver disease	38
Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease	38
Copper deficiency is an independent risk factor for mortality in patients with advanced liver disease	37
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)	37
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial	37
Zinc fingers and homeoboxes 2 is required for diethylnitrosamine‐induced liver tumor formation in C57BL/6 mice	37